

Supplementary information

Harnessing biosynthetic logic for next-generation ADC payloads

Miaomiao Cai,^{†a,d} Xinyuan Pan,^{†a} Wei Shen,^{†a} Sihui Bian,^a Dongbin Hu,^{a,d} Zhao-Xun Liang,^{*c} Yu Tang,^{*a} Xiaohui Fan,^{*a,b,d,e}
and Guang-Lei Ma^{*a,d,e}

^a School of Pharmacy, Zhejiang University, Hangzhou 310058, China. E-mail: guangleima@zju.edu.cn, fanxh@zju.edu.cn, yutang@zju.edu.cn

^b School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. E-mail: fanxh@zju.edu.cn

^c School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore. E-mail: zxliang@ntu.edu.sg

^d State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314102, China.

^e Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.

† These authors contributed equally to this work.

Table S1. Dataset of 555 clinical ADCs. Data were integrated from multiple sources, including public clinical trial registries, regulatory filings, and corporate disclosures, to create a comprehensive dataset covering clinical ADCs up to Dec 2025, which supports the analyses conducted in this study.

| No. | ADC Name | Current R&D Status | Registration/ Approval Date | Payload compound | Payload Category | Antigen/ Target | Company/ Organization |
|-----|--------------------------------------|--------------------|-----------------------------|------------------|------------------|------------------|--|
| 1 | Ado-trastuzumab emtansine (Kadcyla®) | Approved | 2013-02-22 | DM1 | Maytansinoid | HER2; Tubulin | Genentech; Roche |
| 2 | Becotatug vedotin (Meiyouheng®) | Approved | 2025-10-28 | MMAE | Auristatin | EGFR; Tubulin | Shanghai Miracogen (China); Lepu Biopharma (China) |
| 3 | Belantamab mafodotin (Blenrep®) | Approved | 2020-08-05 | MMAF | Auristatin | BCMA;Tubulin | GSK; Baxter Oncology GmbH |
| 4 | Brentuximab vedotin (Adcetris®) | Approved | 2011-08-19 | MMAE | Auristatin | CD30; Tubulin | Seagen Inc; Imagine Institute; Takeda Pharmaceutical |
| 5 | Moxetumomab pasudotox (Lumoxiti®) | Approved | 2018-09-13 | PE38 | PE38 | EGFR | Rakuten Medical Inc; Hikma Pharmaceuticals Plc; |
| 6 | Cetuximab sarotalocan (Akalux®) | Approved | 2020-09-25 | IR700 | Photosensitizers | Trop-2; Topo 1 | Daiichi Sankyo; Astrazeneca |
| 7 | Datopotamab deruxtecan (Datroway®) | Approved | 2024-12-27 | Dxd | Camptothecin | HER2; Tubulin | RemeGen (China) |
| 8 | Disitamab Vedotin (Aidixi®) | Approved | 2021-06-08 | MMAE | Auristatin | NECTIN4; Tubulin | Agensys Inc; Seagen Inc; Astellas Pharma |

| | | | | | | | |
|----|---------------------------------------|----------|------------|---------------|---------------|-----------------------------|--|
| 9 | Enfortumab vedotin (Padcev®) | Approved | 2019-12-18 | MMAE | Auristatin | HER2; TOP1 | Daichi Sankyo; Astrazeneca |
| 10 | Fam-trastuzumab deruxtecan (Enhertu®) | Approved | 2019-12-20 | Dxd | Camptothecin | CD33; DNA | Pfizer; Wyeth-Ayerst Pharmaceuticals |
| 11 | Gemtuzumab ozogamicin (Mylotarg®) | Approved | 2008-01-18 | Calicheamicin | Calicheamicin | CD22; DNA | Haleon Pharmaceutical (China); Celltech Group plc |
| 12 | Inotuzumab Ozogamicin (Besponsa®) | Approved | 2017-06-28 | Calicheamicin | Calicheamicin | CD19; DNA | Adc Therapeutics Sa; Fondazione Italiana Linfomi Onlus; Istituto Clinico Humanitas |
| 13 | Loncastuximab tesirine (Zynlonta®) | Approved | 2021-04-23 | PBD | PBD | FOLR1; Tubulin | Immunogen Inc; Abbvie |
| 14 | Mirvetuximab soravtansine (Elahere®) | Approved | 2022-11-14 | DM4 | Maytansinoid | Tubulin; CD79B | Seagen Inc; Genentech; Roche |
| 15 | Polatuzumab vedotin (Polivy®) | Approved | 2019-06-10 | MMAE | Auristatin | Trop-2; TOP1 | Immunomedics Inc; Gilead Sciences Inc; Ibc Pharmaceuticals Inc; Unicancer |
| 16 | Sacituzumab govitecan (Trodelvy®) | Approved | 2020-04-22 | SN-38 | Camptothecin | Trop-2; TOP1 | Klus Pharma Inc; Blackstone Life Sciences; Merck Sharp & Dohme LLC |
| 17 | Sacituzumab tirumotecan (Jiataile®) | Approved | 2024-11-22 | KL610023 | Camptothecin | c-Met; Microtubule proteins | AbbVie |

| | | | | | | | |
|----|--|----------|------------|-----------------------------------|---------------|---------------|--|
| 18 | Telisotuzumab vedotin (Emrelis®) | Approved | 2025-05-14 | MMAE | Auristatin | TF; Tubulin | Genmab A/S; Zai Lab (China); Baxter Oncology GmbH |
| 19 | Tisotumab vedotin (Tivdak®) | Approved | 2021-09-20 | MMAE | Auristatin | HER2; Tubulin | Kelun-Biotech (China); Fudan University; Klus Pharma |
| 20 | Trastuzumab botidotin (舒泰莱®) | Approved | 2025-10-14 | MMAF | Auristatin | HER2; Tubulin | Zydus Cadila |
| 21 | Trastuzumab emtansine biosimilar (Ujvira®) | Approved | 2021-05-24 | DM1 | Maytansinoid | HER2; TOP1 | Jiangsu Hengrui (China); Atridia Pty Ltd |
| 22 | Trastuzumab rezetecan (Avida®) | Approved | 2025-05-27 | SHR9265 | Camptothecin | CD22 | AstraZeneca |
| 23 | 3H-10000 | Phase I | 2025-10-28 | Undisclosed | Undisclosed | FGFR2b | 3H Pharmaceuticals (China) |
| 24 | ABBV-011 | Phase I | 2018-10-24 | Calicheamicin | Calicheamicin | SEZ6; DNA | AbbVie |
| 25 | ABBV-154 | Phase I | 2022-10-18 | glucocorticoid receptor modulator | GRM | TNF; GR | AbbVie |
| 26 | ABBV-319 | Phase I | 2023-04-26 | glucocorticoid receptor modulator | GRM | GR; CD19 | AbbVie |
| 27 | ABBV-637 | Phase I | 2021-02-23 | BCL-XL inhibitor | Bcl-2 | EGFR; Bcl-X | AbbVie |
| 28 | ABBV-969 | Phase I | 2024-03-08 | A-1770637 | Camptothecin | PSMA; STEAP1 | AbbVie |

| | | | | | | | |
|----|---|---------|------------|-------------|--------------|---------------------------------|---|
| 29 | ADCT-701 | Phase I | 2024-06-17 | PBD | PBD | DLK-1; DNA | Adc Therapeutics Sa; Cancer Research Technology |
| 30 | ADCT-901 | Phase I | 2021-09-09 | PBD | PBD | DNA; KAAG1 | Adc Therapeutics Sa |
| 31 | Ado-trastuzumab emtansine biosimilar | Phase I | 2019-08-13 | DM1 | Maytansinoid | HER2; Tubulin | Jiangsu Hengrui (China) |
| 32 | ADRX-0405 | Phase I | 2024-12-30 | Top1 i | Camptothecin | DNA topoisomerase; STEAP1 | Adcentrx Therapeutics Inc. |
| 33 | ADRX-0706 | Phase I | 2023-09-26 | AP052 | Auristatin | NECTIN4 | Adcentrx Therapeutics Inc. |
| 34 | AGS-67E | Phase I | 2015-12-03 | MMAE | Auristatin | CD37; Tubulin | Agensys Inc. |
| 35 | AGX-101 | Phase I | 2024-07-22 | AP052 | Auristatin | TM4SF1; Tubulin | Angiex Inc. |
| 36 | AK-138-D-1 | Phase I | 2025-02-24 | Dxd | Camptothecin | HER3; TOP1 | Akeso Biopharma (China) |
| 37 | AK-146-D-1 | Phase I | 2025-07-02 | Undisclosed | Undisclosed | Trop-2; NECTIN4 | Akeso Biopharma (China) |
| 38 | ALK-202 | Phase I | 2025-02-10 | Exatecan | Camptothecin | EGFR; c-Met | Shanghai Allink Biotherapeutics (China) |
| 39 | ALT-P7 | Phase I | 2018-01-11 | MMAE | Auristatin | Tubulin; HER2; | Alteogen Inc |
| 40 | ALX-2004 | Phase I | 2025-08-18 | Topo I | Camptothecin | EGF | Alx Oncology Inc |

| | | | | | | | |
|----|---|---------|------------|----------------|--------------|---------------|--|
| 41 | AMG-224 | Phase I | 2015-11-20 | DM1 | Maytansinoid | BCMA | Amgen |
| 42 | AMT-151 | Phase I | 2023-01-25 | DUO-5 | Auristatin | FOLR1 | Multitude Therapeutics (China) |
| 43 | AMT-562 | Phase I | 2024-02-26 | Exatecan | Camptothecin | HER3; TOP1 | Multitude Therapeutics (China) |
| 44 | AMT-676 | Phase I | 2024-06-18 | Exatecan | Camptothecin | CDH17 | Multitude Therapeutics (China) |
| 45 | AMT-707 | Phase I | 2023-08-15 | Exatecan | Camptothecin | CDH6; TOP1 | Multitude Therapeutics (China) |
| 46 | AMT-754 | Phase I | 2024-08-20 | Exatecan | Camptothecin | TF; TOP1 | Multitude Therapeutics (China) |
| 47 | Anti-HER2 monoclonal antibody-MCC-DM1 conjugate | Phase I | 2019-04-01 | DM1 | Maytansinoid | HER2; Tubulin | Shanghai Jiaolian Drug Development (China); Shanghai Pharmaceuticals Holding (China) |
| 48 | Antibody-drug nanocell conjugates | Phase I | 2016-10-25 | Doxorubicin | Doxorubicin | EGFR | Engeneic Ltd |
| 49 | ARX-305 | NDA | 2022-02-15 | Amberstatin269 | Auristatin | CD70; Tubulin | Ambrx Inc |
| 50 | ARX-517 | Phase I | 2020-12-10 | Amberstatin269 | Auristatin | PSMA | Ambrx Inc |
| 51 | ASN-004 | Phase I | 2022-04-08 | MMAF | Auristatin | TPBG | Asana Biosciences Llc |

| | | | | | | | |
|----|----------|---------|------------|-------------|--------------|----------------|--|
| 52 | AT03-65 | Phase I | 2025-01-15 | TCS132 | TCS132 | CLDN6 | Axcynsis Therapeutics Pte Ltd |
| 53 | B-0069 | Phase I | 2019-04-11 | DM1 | Maytansinoid | CD30; Tubulin | Shanghai Pharmaceuticals Holding (China) |
| 54 | BA-1301 | Phase I | 2023-01-11 | Duostatin 5 | Auristatin | Claudin 18.2 | Shandong Boan Biotech (China) |
| 55 | BA-1302 | Phase I | 2024-09-11 | BNLD11 | Auristatin | MELTF | Shandong Boan Biotech (China) |
| 56 | BA-3361 | Phase I | 2024-05-06 | MMAE | Auristatin | NECTIN4 | Bioatla |
| 57 | BAT-8007 | Phase I | 2023-01-17 | Exatecan | Camptothecin | TOP1; NECTIN4 | Bio-Thera Solutions (China) |
| 58 | BAT-8009 | Phase I | 2022-08-02 | Exatecan | Camptothecin | CD276 | Bio-Thera Solutions (China) |
| 59 | BB-1705 | Phase I | 2021-12-24 | Eribulin | Eribulin | EGFR; Tubulin | Bliss Biopharmaceutical (China) |
| 60 | BB-1709 | Phase I | 2022-10-28 | Eribulin | Eribulin | NT5E | Bliss Biopharmaceutical (China) |
| 61 | BB-1710 | Phase I | 2024-03-21 | Eribulin | Eribulin | Updating | Bliss Biopharmaceutical (China) |
| 62 | BB-1712 | Phase I | 2025-04-18 | Eribulin | Eribulin | CD276; Tubulin | Bliss Biopharmaceutical (China) |

| | | | | | | | |
|----|------------------------|---------|------------|---|-------------------------------|---------------------------|--|
| 63 | BC-2027 | Phase I | 2024-04-08 | Undisclosed | Undisclosed | GPC3 | Wuxi Biocity (China) |
| 64 | BC-3195 | Phase I | 2023-03-27 | MMAE | Auristatin | CDH3; Tubulin | Wuxi Biocity (China) |
| 65 | BCG-011 | Phase I | 2024-06-26 | MMAE | Auristatin | Trop-2; EGFR | Biocytogen Pharmaceuticals (Beijing) |
| 66 | Bezetabart debotansine | Phase I | 2018-02-22 | Maytansinoid | Maytansinoid | HLA-DR; Tubulin; | Sutro Biopharma Inc. |
| 67 | BG-C137 | Phase I | 2024-12-09 | topoisomerase inhibitor | Camptothecin | FGFR2 | BeOne Medicines; |
| 68 | BG-C477 | Phase I | 2024-10-03 | Topo1 | Camptothecin | CEA; DNA topoisomerase | BeOne Medicines |
| 69 | BGB-C354 | Phase I | 2024-07-08 | Topo1 | Camptothecin | CD276; TOP1 | BeOne Medicines |
| 70 | BHV-1400 | Phase I | 2025-07-30 | ASGPR-mediated hepatocyte internalization | Immunoglobulin A degraders | IgA | Biohaven Ltd |
| 71 | BL-B16D1 | Phase I | 2024-06-27 | MMAE | Auristatin | EGFR; HER3 | Baili Bio Chengdu Pharmaceutical (China); Sichuan Baili Pharmaceuticals (China) |
| 72 | BL-M05D1 | Phase I | 2024-04-19 | Ed-04 | Camptothecin | Claudin 18.2 | Sichuan Baili Pharmaceuticals (China); SystImmune |

| | | | | | | | |
|----|-----------|---------|------------|----------------|----------------|---------------|--|
| 73 | BL-M09D1 | Phase I | 2025-04-16 | Ed-04 | Camptothecin | Updating | Sichuan Biokin Pharmaceutical (China) |
| 74 | BL-M11D1 | Phase I | 2023-08-02 | Ed-04 | Camptothecin | CD33 | Baili Bio Chengdu Pharmaceutical (China); Sichuan Baili Pharmaceuticals (China) |
| 75 | BL-M14D1 | Phase I | 2024-08-02 | Ed-04 | Camptothecin | DLL3 | Baili Bio Chengdu Pharmaceutical (China); Sichuan Baili Pharmaceuticals (China) |
| 76 | BL-M17D1 | Phase I | 2024-07-24 | MMAE | Auristatin | HER2 | Baili Bio Chengdu Pharmaceutical (China); Sichuan Baili Pharmaceuticals (China) |
| 77 | BL-M19D1 | Phase I | 2024-11-25 | Undisclosed | Undisclosed | Trop-2 | Sichuan Biokin Pharmaceutical (China) |
| 78 | BPT-567 | Phase I | 2024-10-15 | IL18R1 agonist | IL-18R agonist | PD-1; IL18R | Bright Peak Therapeutics Inc. |
| 79 | BR-111 | Phase I | 2025-04-01 | Eribulin | Eribulin | Tubulin; ROR1 | BioRay Biopharmaceutical (China) |
| 80 | BR-111A | Phase I | 2025-03-04 | Undisclosed | Undisclosed | ROR1 | BioRay Biopharmaceutical (China) |
| 81 | BYON-3521 | Phase I | 2022-03-21 | seco-DUBA | Duocarmycin | c-Met | Byondis Bv |

| | | | | | | | |
|----|-----------------------|---------|------------|-------------------------|--------------|---------------|---|
| 82 | BYON-4413 | Phase I | 2024-06-25 | duocarmazine | Duocarmycin | IL3RA | Byondis Bv |
| 83 | Cofetuzumab Pelidotin | Phase I | 2014-10-17 | Aur0101 | Auristatin | Tubulin; PTK7 | AbbVie; Stemcentrx Inc. |
| 84 | CPO-204 | Phase I | 2022-11-29 | Undisclosed | Undisclosed | HER2; Tubulin | CSPC (China) |
| 85 | CX-2051 | Phase I | 2024-01-24 | Camptothecin Derivative | Camptothecin | EpCAM; TOP1 | Cytomx Therapeutics Inc; Immunogen Inc. |
| 86 | DAY-301 | Phase I | 2024-11-18 | Exatecan | Camptothecin | PTK7 | Shanghai Markus Biomedical (China) |
| 87 | DB-1202 | Phase I | 2022-04-24 | Undisclosed | Undisclosed | Updating | Duality Biologics (China) |
| 88 | DB-1312 | Phase I | 2024-04-12 | P1021 | Camptothecin | VTCN1 | Duality Biologics (China) |
| 89 | DB-1317 | Phase I | 2025-09-23 | P1003 | Camptothecin | ADAM9 | Duality Biologics (China) |
| 90 | DB-2304 | Phase I | 2024-10-04 | GR agonist | GRM | CLEC4C | Duality Biologics (China) |
| 91 | DM-002 | Phase I | 2025-02-17 | BLD1002 | Auristatin | MUC1; HER3 | D2M Biotherapeutics (China) |
| 92 | DM-005 | Phase I | 2024-10-31 | BLD1002 | Auristatin | EGFR; TOP1 | Doma Biopharmaceutical (China) |
| 93 | DS-001 | Phase I | 2023-06-13 | Undisclosed | Undisclosed | Trop-2 | Dashi Pharmaceutical (Guangdong) |
| 94 | DXC-005 | Phase I | 2022-07-15 | Tub201 | Tubulysin | MUC1 | Hangzhou DAC Biotechnology (China) |
| 95 | DXC-006 | Phase I | 2024-01-24 | CPT113 | Camptothecin | TOP1; NCAM1 | Hangzhou DAC Biotechnology (China) |

| | | | | | | | |
|-----|---------------------|---------|------------|-------------|--------------|------------------------------|---|
| 96 | DXC-007 | Phase I | 2022-07-07 | Tub255 | Tubulysin | CD33; Tubulin | Hangzhou DAC Biotechnology (China) |
| 97 | DXC-008 | Phase I | 2025-05-15 | Tubulysin B | Tubulysin | STEAP1; PSMA | Hangzhou DAC Biotechnology (China) |
| 98 | DXC-009 | Phase I | 2023-02-20 | Undisclosed | Undisclosed | BCMA | Hangzhou DAC Biotechnology (China) |
| 99 | DXC-014 | Phase I | 2025-09-08 | Top1 i | Camptothecin | CD276; PSMA; TOP1 | Hangzhou DAC Biotechnology (China) |
| 100 | DXC-1002 | Phase I | 2024-01-24 | CPT113 | Camptothecin | TOP1; Trop-2 | Hangzhou DAC Biotechnology (China) |
| 101 | DXC004A | Phase I | 2022-11-04 | Tubulysin B | Tubulysin | EGFR | Hangzhou DAC Biotechnology (China) |
| 102 | EBC-129 | Phase I | 2023-04-28 | MMAE | Auristatin | CEACAM6; CEACAM5; Tubulin | Experimental Drug Development Centre |
| 103 | Emiltatug Ledadotin | Phase I | 2022-08-15 | AF-HPA | Auristatin | Tubulin; VTCN1 | Mersana Therapeutics Inc. |
| 104 | ESG-406 | Phase I | 2025-04-22 | Undisclosed | Undisclosed | Updating | Shanghai Escugen Biotechnology (China) |
| 105 | ETx-22 | Phase I | 2024-03-05 | Exatecan | Camptothecin | NECTIN4 | Emergence Therapeutics AG |

| | | | | | | | |
|-----|------------------------------------|---------|------------|----------------|--------------|------------------|--|
| 106 | EVOLVE 104 antibody-drug conjugate | Phase I | 2025-08-15 | CD2 agonist | CD2 agonist | RAET1L; ULBP2 | EvolveImmune Therapeutics Inc. |
| 107 | Felmetatug vedotin | Phase I | 2022-01-12 | MMAE | Auristatin | Tubulin; VTCN1 | Seagen Inc. |
| 108 | FPI-2068 | Phase I | 2023-04-12 | 225Ac | Radionuclide | EGFR; c-Met | Fusion Pharmaceuticals Inc; AstraZeneca |
| 109 | FZ-AD004 | Phase I | 2023-08-01 | BB05 | Camptothecin | Trop-2 | Shanghai Fudan Zhangjiang Bio Pharmaceutical (China) |
| 110 | FZ-AD005 | Phase I | 2024-07-03 | DXd | Camptothecin | DLL3; TOP1 | Shanghai Fudan Zhangjiang Bio Pharmaceutical (China) |
| 111 | GB-251 | Phase I | 2018-05-08 | MMAE | Auristatin | Tubulin; HER2 | Genor Biopharma (China) |
| 112 | GenSci-139 | Phase I | 2025-10-24 | Top1 GSC5181 | Camptothecin | EGFR; HER2; TOP1 | Changchun GeneScience Pharmaceuticals (China) |
| 113 | GenSci-143 | Phase I | 2025-10-31 | Top1 GSC5181 | Camptothecin | CD276; PSMA | Changchun GeneScience Pharmaceuticals (China) |
| 114 | GR-1017 | Phase I | 2025-01-13 | Top1 | Camptothecin | FGFR3; TOP1 | GeneQuantum (China); Aimed Bio Inc. |
| 115 | HBM-9033 | Phase I | 2023-08-28 | Top1 i | Camptothecin | MSLN | Nona Biosciences (China) |

| | | | | | | | |
|-----|----------|---------|------------|----------------|--------------|--------------|---|
| 116 | HDM-2012 | Phase I | 2025-06-30 | Top1 i | Camptothecin | MUC17 | Hangzhou Zhongmei Huadong Pharmaceutical (China) |
| 117 | HDM-2017 | Phase I | 2025-09-22 | CPT derivative | Camptothecin | CDH17 | Hangzhou Zhongmei Huadong Pharmaceutical (China) |
| 118 | HDM-2020 | Phase I | 2025-07-14 | Top1 i | Camptothecin | FGFR2b | Hangzhou Zhongmei Huadong Pharmaceutical (China) |
| 119 | HLX-42 | Phase I | 2023-10-27 | Topo1 | Camptothecin | EGFR; TOP1 | Shanghai Henlius Biotech (China) |
| 120 | HS-20110 | Phase I | 2025-01-14 | Topo1 | Camptothecin | CDH17 | Shanghai Hansoh Biomedical (China); Changzhou Hansoh Pharmaceutical (China) |
| 121 | HS-20122 | Phase I | 2025-04-29 | Undisclosed | Undisclosed | EGFR; c-Met | Shanghai Hansoh Biomedical (China) |
| 122 | HS-20124 | Phase I | 2024-10-30 | SHR9265 | Camptothecin | CDH6; Trop-2 | Hansoh BioMedical R&D Company |
| 123 | HY-0001 | Phase I | 2025-08-28 | MMAE | Auristatin | Updating | Sichuan Huiyu Pharmaceutical (China) |
| 124 | IBI-3001 | Phase I | 2025-01-10 | Topo/Exatecan | Camptothecin | CD276; EGFR | Innovent Biologics (China) |

| | | | | | | | |
|-----|---|---------|------------|-------------------|--------------|--------------------|---|
| 125 | IBI-3005 | Phase I | 2025-01-08 | Camptothecin | Camptothecin | TOP1; HIF1A | Innovent Biologics (China) |
| 126 | IBI-3007 | Phase I | 2025-03-04 | TLR7/8 agonist | TLR | Trop-2; TLR7; TLR8 | Innovent Biologics (China) |
| 127 | IBI-3009 | Phase I | 2024-12-04 | Undisclosed | Undisclosed | DLL3; TOP1 | Innovent Biologics (China) |
| 128 | IBI-3010 | Phase I | 2025-01-26 | NT1 | Camptothecin | TOP1; FOLR1 | Innovent Biologics (China) |
| 129 | IBI-3020 | Phase I | 2025-04-17 | Undisclosed | Undisclosed | CEACAM5 | Innovent Biologics (China) |
| 130 | ICP-B794 | Phase I | 2025-07-03 | TOP1 i | Camptothecin | CD276 | InnoCare Pharma |
| 131 | IKS-03 | Phase I | 2023-09-05 | PBD | PBD | CD19 | Legochem Biosciences Inc; Novimmune Sa |
| 132 | IMGN-151 | Phase I | 2023-01-11 | DM21 | Maytansinoid | FOLR1; Tubulin | Immunogen Inc. |
| 133 | INA-03 | Phase I | 2020-05-29 | MMAE | Auristatin | TfR1; Tubulin | Inatherys |
| 134 | Indium-111-DOTA-girentuximab-IRDye800CW | Phase I | 2015-06-01 | ¹¹¹ In | Radionuclide | CA9 | Radboud University Nijmegen |
| 135 | IPH-4502 | Phase I | 2024-09-23 | Exatecan | Camptothecin | TOP1; NECTIN4 | Innate Pharma SA |
| 136 | JNJ-89862175 | Phase I | 2025-10-10 | Undisclosed | Undisclosed | ENPP3 | Janssen Research & Development Llc |

| | | | | | | | |
|-----|-----------------------|---------|------------|-------------------------|--------------|---------------------------|---|
| 137 | JS-107 | Phase I | 2022-03-29 | MMAE | Auristatin | Claudin 18.2 | Shanghai Junshi Biosciences (China) |
| 138 | JS-108 | Phase I | 2020-10-28 | Tub196 | Tubulysin | Trop-2; Tubulin | Hangzhou DAC Biotechnology (China) |
| 139 | JSKN-022 | Phase I | 2025-10-14 | Alphatecan | Camptothecin | TOP1; PD-L1; ITGB6; ITGB8 | Alphamab Oncology (China) |
| 140 | KH-815 | Phase I | 2025-04-30 | TOP1 and RNA POL II | Camptothecin | Trop-2 | Chengdu Kanghong Biotechnology (China) |
| 141 | LCB-71 | Phase I | 2022-01-03 | PBD | PBD | ROR1; DNA | Legochem Biosciences Inc; Abl Bio Inc. |
| 142 | LFD-200 | Phase I | 2025-10-06 | GR regulator | GRM | VISTA | Lifordi Immunotherapeutics Inc; |
| 143 | LNCB-74 | Phase I | 2025-01-07 | MMAE | Auristatin | VTCN1; DNA | Nextcure Inc; LigaChem Biosciences Inc. |
| 144 | Losatuxizumab vedotin | Phase I | 2015-01-09 | MMAE | Auristatin | EGFR; Tubulin | AbbVie |
| 145 | Lupartumab amadotin | Phase I | 2014-05-22 | Auristatin W Derivative | Auristatin | LYPD3; Tubulin | Bayer |
| 146 | LY-4175408 | Phase I | 2025-07-28 | Exatecan | Camptothecin | PTK7; TOP1 | Lilly |
| 147 | M-1231 | Phase I | 2021-01-13 | SC209 | Hemiasterlin | EGFR; MUC1 | Emd Serono Research & Development Institute Inc;Merck |

| | | | | | | | |
|-----|------------------------|---------|------------|-------------|--------------|--------------|---|
| 148 | M-3554 | Phase I | 2024-11-08 | Exatecan | Camptothecin | GD2; TOP1 | Merck |
| 149 | MEDI-2228 | Phase I | 2018-05-08 | PBD | PBD | BCMA | Medimmune Llc. |
| 150 | MG-1901 | Phase I | 2022-12-01 | Undisclosed | Undisclosed | Updating; | Shanghai MabGen Biotech (China) |
| 151 | MG-2001 | Phase I | 2022-12-01 | Undisclosed | Undisclosed | Updating; | Shanghai MabGen Biotech (China) |
| 152 | MG-2002A | Phase I | 2022-12-01 | Undisclosed | Undisclosed | Updating; | Shanghai MabGen Biotech (China) |
| 153 | MGC-026 | Phase I | 2024-03-06 | Exatecan | Camptothecin | TOP1; CD276 | Macrogenics Inc. |
| 154 | MGC-028 | Phase I | 2025-02-13 | Exatecan | Camptothecin | ADAM9; TOP1 | Macrogenics Inc. |
| 155 | MHB-009C | Phase I | 2025-01-03 | Undisclosed | Undisclosed | VTCN1; TOP1 | Minghui Pharmaceutical (China) |
| 156 | Mirzotamab clezutoclax | Phase I | 2018-07-13 | Clezutoclax | Bcl-2 | CD276; Bcl-X | AbbVie |
| 157 | MK-6204 | Phase I | 2024-12-12 | Undisclosed | Undisclosed | Updating | Sichuan Kelun Botai Biomedicine (China) |
| 158 | MRG001 | Phase I | 2019-05-05 | MMAE | Auristatin | CD20 | Shanghai Miracogen (China); |
| 159 | MYTX-011 | Phase I | 2023-03-23 | MMAE | Auristatin | c-Met | Mythic Therapeutics Inc. |

| | | | | | | | |
|-----|--|---------|------------|-------------|----------------|----------------|---|
| 160 | NBT-508 | Phase I | 2021-02-10 | Undisclosed | Undisclosed | CD79B | NewBio Therapeutics (China); Tot Biopharm (China) |
| 161 | NC-18 | Phase I | 2024-02-05 | MMAF | Auristatin | HER2 | Novacyte Therapeutics (China) |
| 162 | Nectin-4 targeting antibody drug conjugate 1 | Phase I | 2025-03-01 | Undisclosed | Undisclosed | NECTIN4 | Lilly |
| 163 | Nectin-4 targeting antibody drug conjugate 2 | Phase I | 2025-03-01 | Undisclosed | Undisclosed | NECTIN4 | Lilly |
| 164 | NN-3201 | Phase I | 2025-02-03 | MMAE | Auristatin | KIT; Tubulin | Novelty Nobility Inc |
| 165 | Oba-01 | Phase I | 2023-12-13 | MMAE | Auristatin | DR5 | Yantai Heyuan Aidis Biomedical Technology (China) |
| 166 | Oberotatug ravtansine | Phase I | 2017-08-28 | DM4 | Maytansinoid | LY75; Tubulin | Oxford Biotherapeutics Ltd; Menarini |
| 167 | OMTX-705 | Phase I | 2022-10-20 | TAM470 | Maytansinoid | Tubulin; FAP | Oncomatrix Biopharma SI |
| 168 | ORM-6151 | Phase I | 2023-11-06 | SMol006 | GSPT1 degrader | GSPT1; CD33 | Orum Therapeutics Inc. |
| 169 | PF-08046031 | Phase I | 2025-05-01 | MMAE | Auristatin | MELTF; Tubulin | Pfizer |
| 170 | PF-08046032 | Phase I | 2025-05-08 | MMAE | Auristatin | IL2RA; Tubulin | Pfizer |

| | | | | | | | |
|-----|---|---------|------------|-------------|--------------|---------------|---|
| 171 | PF-08046876 | Phase I | 2025-08-20 | AMDCPT | Camptothecin | ITGB6; TOP1 | Pfizer |
| 172 | PHN-010 | Phase I | 2024-07-01 | Undisclosed | Undisclosed | Updating | Pheon Therapeutics Ltd |
| 173 | PHN-012 | Phase I | 2025-09-23 | Undisclosed | Undisclosed | Updating | Pheon Therapeutics Inc. |
| 174 | PM1300 | Phase I | 2025-06-20 | Undisclosed | Undisclosed | EGFR; HER3 | Biotheus (China) |
| 175 | QLS-5132 | Phase I | 2025-05-01 | Undisclosed | Undisclosed | CLDN6 | Qilu Pharmaceutical (China) |
| 176 | RC-248 | Phase I | 2024-01-09 | Undisclosed | Undisclosed | DR5 | RemeGen (China) |
| 177 | Recombinant anti-HER2 human monoclonal antibody-DM1 | Phase I | 2019-06-18 | DM1 | Maytansinoid | Tubulin; HER2 | Zhejiang Hisun Pharmaceutical (China); Beijing Mabworks Biotech (China) |
| 178 | RG-6148 | Phase I | 2018-04-17 | PBD | PBD | HER2 | Genentech, Roche |
| 179 | SBO-154 | Phase I | 2025-07-17 | Undisclosed | Undisclosed | MUC1 | Sun Pharmaceutical Advanced Research Co Ltd |
| 180 | Serclutamab talirine | Phase I | 2017-10-10 | SGD-1882 | PBD | DNA; EGFR | AbbVie |
| 181 | SG-2918 | Phase I | 2023-12-26 | Undisclosed | Undisclosed | Tubulin | Hangzhou Shangjian Biotechnology (China) |
| 182 | SGN-35C | Phase I | 2024-05-28 | Undisclosed | Undisclosed | TOP1; CD30 | Seagen Inc. |

| | | | | | | | |
|-----|--------------|---------|------------|-------------------------|--------------|-------------------|---|
| 183 | SGN-35T | Phase I | 2024-02-29 | Undisclosed | Undisclosed | HIF1A; TOP1; CD30 | Seagen Inc. |
| 184 | SGN-CEACAM5C | Phase I | 2023-11-20 | Undisclosed | Undisclosed | CEACAM5; TOP1 | Seagen Inc; Sanofi |
| 185 | SGN-STNV | Phase I | 2020-12-14 | MMAE | Auristatin | Tubulin | Seagen Inc. |
| 186 | SHR-1904 | Phase I | 2022-08-24 | Undisclosed | Undisclosed | HER2 | Jiangsu Hengrui (China) |
| 187 | SHR-4394 | Phase I | 2025-01-22 | Undisclosed | Undisclosed | Updating | Jiangsu Hengrui (China) |
| 188 | SIBP-A13 | Phase I | 2023-09-19 | DXd | Camptothecin | HER3 | Shanghai Institute of Biological Products (China) |
| 189 | SIBP-A17 | Phase I | 2024-07-11 | DXd | Camptothecin | HER2 | Shanghai Institute of Biological Products (China) |
| 190 | SIBP-A18 | Phase I | 2025-06-15 | DXd | Camptothecin | Claudin 18.2 | Shanghai Institute of Biological Products (China) |
| 191 | SIBP-A19 | Phase I | 2025-05-21 | DXd | Camptothecin | Updating | Shanghai Institute of Biological Products (China) |
| 192 | SIM-0505 | Phase I | 2025-02-26 | Camptothecin Derivative | Camptothecin | CDH6; TOP1 | Simcere Zaiming Pharmaceutical (China) |
| 193 | SIM-0609 | Phase I | 2025-09-05 | CPT116 | Camptothecin | CDH17; TOP1 | Simcere (China) |
| 194 | SIM-0686 | Phase I | 2025-04-08 | Camptothecin Derivative | Camptothecin | FGFR2 | Simcere Zaiming Pharmaceutical (China) |

| | | | | | | | |
|-----|----------|---------|------------|------------------|-----------------|---------------|---|
| 195 | SKB-445 | Phase I | 2025-02-05 | Undisclosed | Undisclosed | Updating | Sichuan Kelun Botai Biomedicine (China) |
| 196 | SKB-500 | Phase I | 2024-12-13 | Undisclosed | Undisclosed | CD276 | Sichuan Kelun Botai Biomedicine (China) |
| 197 | SKB-501 | Phase I | 2024-11-25 | Undisclosed | Undisclosed | Updating | Sichuan Kelun Botai Biomedicine (China) |
| 198 | SMP-656 | Phase I | 2024-02-01 | Eribulin | Eribulin | HER2; Tubulin | Xiling Lab (China) |
| 199 | SN-001 | Phase I | 2024-04-09 | Undisclosed | Undisclosed | Updating | Sinoway (China) |
| 200 | STX-0712 | Phase I | 2025-03-13 | CCR2 antagonists | CCR2 antagonist | CCR2 | Solu Therapeutics Inc. |
| 201 | SYD-1875 | Phase I | 2020-02-28 | seco-DUBA | Duocarmycin | TPBG | Synthon Bv |
| 202 | SYHD001 | Phase I | 2024-07-16 | MMAE | Auristatin | Updating | Sanyou Biopharmaceuticals (China); Hangzhou Zhongmei Huadong Pharmaceutical (China) |
| 203 | SYS-6005 | Phase I | 2025-03-31 | MMAE | Auristatin | ROR1; Tubulin | CSPC (China) |
| 204 | SYS-6023 | Phase I | 2024-07-08 | Undisclosed | Undisclosed | HER3 | CSPC Megalith Biopharmaceutial (China) |

| | | | | | | | |
|-----|----------------------|---------|------------|-------------|--------------|-------------------------|---|
| 205 | SYS-6040 | Phase I | 2025-03-20 | Undisclosed | Undisclosed | HER2; Tubulin; DLL3 | CSPC Megalith Biopharmaceutical (China) |
| 206 | SYS-6041 | Phase I | 2025-03-28 | Undisclosed | Undisclosed | HER2; Tubulin; FOLR1 | CSPC Megalith Biopharmaceutical (China) |
| 207 | T-320 | Phase I | 2024-11-12 | Undisclosed | Undisclosed | Updating | Nanolattix Biotechnology (China) |
| 208 | TGW-101 | Phase I | 2025-05-07 | MMAE | Auristatin | TAG-72; Tubulin | Tagworks Pharmaceuticals BV |
| 209 | Tilatamig samrotecan | Phase I | 2022-12-22 | AZ14170132 | Camptothecin | EGFR; c-Met; TOP1 | AstraZeneca |
| 210 | TJ-101 | Phase I | 2025-07-01 | PY-4CAR2 | Camptothecin | EGFR; CD276; TOP1 | Phrontline Biopharma (China) |
| 211 | TORL-2-307-ADC | Phase I | 2022-02-02 | MMAE | Auristatin | Claudin 18.2 | Torl Biotherapeutics LLC |
| 212 | TORL-3-600 | Phase I | 2023-09-29 | MMAE | Auristatin | Tubulin; CDH17 | Torl Biotherapeutics LLC |
| 213 | TORL-4-500 | Phase I | 2023-12-04 | MMAR | Auristatin | TAA | Torl Biotherapeutics LLC |
| 214 | TQB-2101 | Phase I | 2025-04-01 | Dxd | Camptothecin | ROR1 | Nanjing Chia Tai Tianqing Pharmaceutical (China) |
| 215 | TQB-2103 | Phase I | 2023-07-04 | Dxd | Camptothecin | Claudin 18.2 | Nanjing Chia Tai Tianqing Pharmaceutical (China) |

| | | | | | | | |
|-----|-------------------------|---------|------------|------------------------------|--------------|-----------------------|--|
| 216 | TQB-6411 | Phase I | 2025-06-13 | Dxd | Camptothecin | EGFR; c-Met | Nanjing Chia Tai Tianqing Pharmaceutical (China); |
| 217 | Trastuzumab imbotolimod | Phase I | 2023-08-01 | Immunostimulants/TLR agonist | Undisclosed | HER2 | Bolt Biotherapeutics Inc. |
| 218 | TRPH-222 | Phase I | 2018-10-15 | DM1 | Maytansinoid | CD22 | Catalent Inc. |
| 219 | VIP943 | Phase I | 2023-09-13 | KSPi | KSPi | IL3RA | Bayer |
| 220 | XB-002 | Phase I | 2021-06-07 | MMAE | Auristatin | TF | Iconic Therapeutics Inc. |
| 221 | XB-010 | Phase I | 2024-08-06 | MMAE | Auristatin | TPBG | Exelixis Inc. |
| 222 | XB-371 | Phase I | 2025-08-18 | KSPi | KSPi | DNA topoisomerase; TF | Catalent Inc; Exelixis Inc. |
| 223 | XMT-2056 | Phase I | 2023-01-24 | STING agonist-20 | STING | STING; HER2 | Mersana Therapeutics Inc. |
| 224 | XZP-KM501 | Phase I | 2023-03-02 | MMAE | Auristatin | HER2; Tubulin | Shandong Xuanzhu Pharmaceutical Technology (China) |
| 225 | YL-203 | Phase I | 2024-01-01 | Camptothecin | Camptothecin | TOP1 | Suzhou Medilink Therapeutics (China) |
| 226 | YL-204 | Phase I | 2024-01-01 | Camptothecin | Camptothecin | TOP1 | Suzhou Medilink Therapeutics (China) |

| | | | | | | | |
|-----|-----------------------|----------|------------|------------------|--------------|---------------|---------------------------------------|
| 227 | YL-211 | Phase I | 2024-05-01 | Camptothecin | Camptothecin | c-Met | Suzhou Medilink Therapeutics (China) |
| 228 | YL-215 | Phase I | 2024-01-01 | Topo1 | Camptothecin | MSLN | Suzhou Medilink Therapeutics (China) |
| 229 | YL-217 | Phase I | 2025-07-02 | Camptothecin | Camptothecin | TOP1; CDH17 | Suzhou Medilink Therapeutics (China) |
| 230 | YL-221 | Phase I | 2024-01-01 | Camptothecin | Camptothecin | EGFR | Suzhou Medilink Therapeutics (China). |
| 231 | YL-222 | Phase I | 2024-01-01 | YL0010014 | Camptothecin | PD-L1 | Suzhou Medilink Therapeutics (China). |
| 232 | Zanidatamab zovodotin | Phase I | 2019-04-15 | MMAE | Auristatin | HER2; Tubulin | Zymeworks Inc. |
| 233 | ZPC-21 | Phase I | 2025-02-26 | HC74 | HC74 | ROR1; TOP1 | Zentalis Pharmaceuticals Inc. |
| 234 | ZV-0203 | Phase I | 2021-12-17 | Duostatin-5/MMAF | Auristatin | HER2; Tubulin | Hangzhou Adcoris Biopharmacy (China) |
| 235 | ZW-191 | Phase I | 2024-07-25 | ZD06519 | Camptothecin | TOP1; FOLR1 | Zymeworks Inc. |
| 236 | ZW-251 | Phase I | 2025-09-01 | ZD06519 | Camptothecin | GPC3; TOP1 | Zymeworks Inc. |
| 237 | 7MW-3711 | Phase II | 2023-08-28 | Mtoxin | Camptothecin | CD276; TOP1 | Mabwell (Shanghai) Bioscience (China) |

| | | | | | | | |
|-----|---|-----------|------------|------------------------------|--------------|---------------|--|
| 238 | 7MW-4911 | Phase II | 2025-09-24 | MF-6 | Camptothecin | CDH17; TOP1 | Mabwell (Shanghai) Bioscience (China) |
| 239 | 89Zr-Patritumab deruxtecan | Phase II | 2025-03-03 | Exatecan | Camptothecin | HER3; TOP1 | Daiichi Sankyo; The Netherlands Cancer Institute; Daiichi Sankyo Inc. |
| 240 | 9MW-2921 | Phase II | 2023-08-28 | Mtoxin | Camptothecin | TOP1; Trop-2 | Mabwell (Shanghai) Bioscience (China) |
| 241 | ABBV-3373 | Phase II | 2019-03-27 | GRM | GRM | TNF | AbbVie |
| 242 | ABBV-706 | Phase III | 2025-08-28 | A-1743332 | Camptothecin | SEZ6; TOP1 | AbbVie |
| 243 | ACR-246 | Phase II | 2024-10-29 | D2102 | D2102 | TPBG | Hangzhou Adcoris Biopharmacy (China) |
| 244 | ADCE-D01 | Phase II | 2025-06-05 | P1021 | Camptothecin | MRC2; Tubulin | Adcendo APS |
| 245 | Ado Trastuzumab Emtansine biosimilar | Phase III | 2019-08-09 | DM1 | Maytansinoid | HER2; Tubulin | Hetero Biopharma Ltd |
| 246 | ALE-P02 | Phase II | 2024-10-02 | tubulin inhibitor | Undisclosed | CLDN1 | Alentis Therapeutics AG |
| 247 | ALE-P03 | Phase II | 2025-08-26 | topoisomerase I inhibitor | Camptothecin | CLDN1 | Alentis Therapeutics AG |

| | | | | | | | |
|-----|---|-----------|------------|----------------|--------------|---------------|---|
| 248 | ALK-201 | Phase II | 2024-10-24 | Exatecan | Camptothecin | FGFR2b | Shanghai Allink Biotherapeutics (China) |
| 249 | AMT-116 | Phase II | 2024-05-07 | KL610023 | Camptothecin | CD44 | Multitude Therapeutics (China) |
| 250 | AMT-253 | Phase II | 2024-01-31 | Exatecan | Camptothecin | MCAM; TOP1 | Multitude Therapeutics (China) |
| 251 | Anetumab ravtansine | Phase II | 2015-12-03 | DM4 | Maytansinoid | MSLN; Tubulin | Morphosys Ag; Bayer |
| 252 | Anti TROP2 antibody drug conjugate ADC | Phase II | 2023-03-30 | Undisclosed | Undisclosed | Trop-2 | Fudan University |
| 253 | Anti-CD46 antibody drug conjugate | Phase II | 2022-01-19 | MMAE | Auristatin | MCP; Tubulin | Fibrogen; Fortis Therapeutics |
| 254 | anti-HER2 ADC | Phase II | 2022-11-01 | Aur0101 | Auristatin | HER2 | Pfizer; Fudan University |
| 255 | Antibody–drug conjugates based pyrrolobenzodiazepines | Phase II | 2022-09-06 | PBD | PBD | Updating | AstraZeneca; Genentech |
| 256 | ANV-600 | Phase II | 2024-05-29 | ANV419 | IL-2R agoist | IL2R | Anaveon AG |
| 257 | Anvatabart opadotin | Phase III | 2025-04-10 | Amberstatin269 | Auristatin | Tubulin; HER2 | Ambrx Inc |
| 258 | ATG-022 | Phase II | 2024-03-20 | MMAE | Auristatin | Claudin 18.2 | Antengene (China) |
| 259 | AZD-0516 | Phase II | 2025-10-01 | Exatecan | Camptothecin | STEAP2; TOP1 | AstraZeneca |

| | | | | | | | |
|-----|----------|-----------|------------|----------------|--------------|--------------------------|--|
| 260 | AZD-4360 | Phase II | 2025-04-29 | Belotecan | Camptothecin | TOP1; Claudin 18.2 | AstraZeneca |
| 261 | AZD-4512 | Phase II | 2025-07-07 | Undisclosed | Undisclosed | CD22 | AstraZeneca |
| 262 | AZD-9829 | Phase II | 2024-01-31 | AZ14170132 | Camptothecin | TOP1; IL3RA | AstraZeneca |
| 263 | AZD5335 | Phase III | 2025-10-16 | AZ14170132 | Camptothecin | FOLR1; TOP1 | AstraZeneca |
| 264 | BAT-8006 | Phase III | 2025-06-11 | Exatecan | Camptothecin | FOLR1; TOP1 | Bio-Thera Solutions (China) |
| 265 | BAT-8008 | Phase II | 2024-04-12 | Exatecan | Camptothecin | Trop-2; TOP1 | Bio-Thera Solutions (China) |
| 266 | BAT-8010 | Phase II | 2024-05-08 | TOP1i | Camptothecin | TOP1; HER2 | Bio-Thera Solutions (China) |
| 267 | BB-1701 | Phase II | 2023-03-07 | Eribulin | Eribulin | HER2; TUBB1 | Bliss Biopharmaceutical (China) |
| 268 | BDC-4182 | Phase II | 2025-05-26 | TLR7/8 agonist | TLR | Claudin 18.2; Tubulin | Bolt Biotherapeutics Inc |
| 269 | BIO-106 | Phase II | 2022-03-25 | Tlr-7/8 | TLR | Trop-2 | Bionecure Therapeutics (China) |
| 270 | BL-M02D1 | Phase II | 2023-09-04 | Ed-04 | Camptothecin | Trop-2 | Baili Bio Chengdu Pharmaceutical (China); Sichuan Baili Pharmaceuticals (China) |

| | | | | | | | |
|-----|-----------------------|-----------|------------|-------------|--------------|------------------|---|
| 271 | BL-M07D1 | Phase III | 2024-05-08 | Ed-04 | Camptothecin | HER2 | SystImmune; Sichuan Baili Pharmaceuticals (China) |
| 272 | BM7PE | Phase II | 2020-08-31 | PE40 | PE38 | MUC1 | Oslo University Hospital |
| 273 | BRY-812 | Phase II | 2025-10-24 | MMAE | Auristatin | ZIP6 | BioRay Biopharmaceutical (China) |
| 274 | Bulumtatug fuvedotin | Phase III | 2023-12-29 | MMAE | Auristatin | NECTIN4; Tubulin | Mabwell (Shanghai) Bioscience (China) |
| 275 | C225-ILS-DOX | Phase II | 2023-06-12 | Doxorubicin | Doxorubicin | TOP2; EGFR | Universitaetsspitals Basel |
| 276 | Camidanlumab tesirine | Phase II | 2019-09-13 | PBD | PBD | DNA; IL2RA | Adc Therapeutics Sa; Genmab A/S |
| 277 | Caxmotabart Entudotin | Phase III | 2023-03-28 | MMAF | Auristatin | HER2; Tubulin | Legochembio; Iksuda Therapeutics |
| 278 | CM518D1 | Phase II | 2025-06-03 | Undisclosed | Undisclosed | CDH17 | Keymed Biomedical Technology |
| 279 | CMG-901 | Phase III | 2024-03-04 | MMAE | Auristatin | Claudin 18.2 | Keymed Biomedical Technology; AstraZeneca |
| 280 | CUBT-906 | Phase II | 2023-12-01 | PBD | PBD | NCAM1 | Curative Biotechnology Inc. |
| 281 | CX-2029 | Phase II | 2018-06-15 | MMAE | Auristatin | TfR1 | Cytomx Therapeutics Inc; AbbVie |
| 282 | DB-1305 | Phase II | 2022-07-19 | P1021 | Camptothecin | Trop-2; TOP1 | Duality Biologics (China) |
| 283 | DB-1310 | Phase II | 2023-04-10 | P1021 | Camptothecin | HER3; TOP1 | Duality Biologics (China) |

| | | | | | | | |
|-----|------------------------------|-----------|------------|------------|--------------|------------------|--|
| 284 | DB-1311 | Phase II | 2023-08-17 | P1021 | Camptothecin | CD276; TOP1 | Duality Biologics (China); Biontech Se; Biotheus |
| 285 | DB-1418 | Phase II | 2025-06-04 | P1021 | Camptothecin | EGFR; HER3; TOP1 | Duality Biologics (China); Avenzo Therapeutics |
| 286 | DB-1419 | Phase II | 2024-09-03 | P1003 | Camptothecin | CD276; PD-L1 | Duality Biologics (China) |
| 287 | Debio-1562M | Phase II | 2025-05-30 | DM1 | Maytansinoid | CD37 | Debiopharm International Sa |
| 288 | Depatuxizumab mafodotin | Phase III | 2015-01-04 | MMAF | Auristatin | EGFR; Tubulin | AbbVie |
| 289 | DS-3939 | Phase II | 2023-08-18 | Exatecan | Camptothecin | MUC1; TOP1 | Daiichi Sankyo Inc. |
| 290 | DX126-262 | Phase II | 2021-11-17 | Tub114 | Tubulysin | HER2; Tubulin | Hangzhou DAC Biotechnology (China) |
| 291 | DYNE-251 | Phase II | 2022-08-12 | PMO | PMO | TfR1; DMD | Dyne Therapeutics Inc. |
| 292 | E-EDV-D682 | Phase II | 2025-09-01 | PNU-159682 | Doxorubicin | TOP2; EGFR | Engeneic Ltd |
| 293 | Enapotamab vedotin | Phase II | 2016-11-23 | MMAE | Auristatin | AXL; Tubulin | Seagen Inc; Genmab A/S |
| 294 | Epratuzumab-cys- tesirine | Phase II | 2018-08-24 | PBD | PBD | DNA; CD22 | Adc Therapeutics Sa |
| 295 | ESG-401 | Phase III | 2024-07-11 | SN-38 | Camptothecin | Trop-2; TOP1 | Shanghai Escugen Biotechnology (China); Qilu Pharmaceutical (China) |

| | | | | | | | |
|-----|-----------------------------------|-----------|------------|-------------|--------------|----------------|---|
| 296 | Farletuzumab ecteribulin | Phase II | 2020-08-06 | Eribulin | Eribulin | FOLR1; Tubulin | Eisai; Morphotek Inc; Bristol Myers Squibb |
| 297 | FDA018 Antibody Drug Conjugate | Phase III | 2024-08-09 | SN-38 | Camptothecin | Trop-2 | Shanghai Fudan Zhangjiang Bio Pharmaceutical (China); Fudan University |
| 298 | FDA022 Antibody Drug Conjugate | Phase II | 2024-05-13 | BB05 | Camptothecin | HER2 | Shanghai Fudan Zhangjiang Bio Pharmaceutical (China) |
| 299 | FS001 | Phase II | 2025-10-30 | Top1 i | Camptothecin | TOP1 | Foreseen Biotechnology (China); Shanghai Escugen Biotechnology (China) |
| 300 | Gancotamab | Phase II | 2017-12-13 | Doxorubicin | Doxorubicin | TOP2; HER2 | Merrimack Pharmaceuticals Inc. |
| 301 | Glembatumumab vedotin | Phase II | 2006-06-01 | MMAE | Auristatin | Tubulin; GPNMB | Celldex Therapeutics |
| 302 | GQ-1001 | Phase II | 2022-10-01 | DM1 | Maytansinoid | HER2 | GeneQuantum (China) |
| 303 | GQ-1005 | Phase III | 2024-12-01 | Topo1/Dxd | Camptothecin | HER2; TOP1 | GeneQuantum (China); Shanghai Henlius Biotech (China) |
| 304 | GQ-1010 | Phase II | 2024-04-22 | Topolx | Camptothecin | Trop-2; TOP1 | GeneQuantum (China) |
| 305 | GR-1014 | Phase II | 2024-07-26 | Undisclosed | Undisclosed | Updating | GeneQuantum (China) |

| | | | | | | | |
|-----|-------------|-----------|------------|-------------------------|--------------|---------------|---|
| 306 | GSK-5733584 | Phase III | 2025-03-07 | HS-9265 | Camptothecin | VTCN1; TOP1 | Changzhou Hansoh Pharmaceutical (China); GSK; Hansoh BioMedical R&D Company; 江苏豪森药业集团有限公司; Shanghai Hansoh Biomedical (China) |
| 307 | HB-0052 | Phase II | 2024-09-01 | Undisclosed | Undisclosed | NT5E; TOP1 | Changzhou Hansoh Pharmaceutical (China); GSK; Hansoh BioMedical R&D Company; 江苏豪森药业集团有限公司; Shanghai Hansoh Biomedical (China) |
| 308 | HDM-2005 | Phase II | 2025-07-09 | Camptothecin Derivative | Camptothecin | ROR1; Tubulin | Hangzhou Zhongmei Huadong Pharmaceutical (China) |
| 309 | HDP-101 | Phase II | 2022-02-07 | Amanitin | Amanitin | RNAP; BCMA | Heidelberg Pharma AG |
| 310 | HLX-43 | Phase II | 2025-01-26 | camptothecin-based | Camptothecin | PD-L1; TOP1 | Shanghai Henlius Biotech (China) |
| 311 | HMBD-501 | Phase II | 2025-10-01 | Exatecan | Camptothecin | HER3; TOP1 | Hummingbird Bioscience |

| | | | | | | | |
|-----|------------------------|-----------|------------|--------------|------------------|--------------------------|--|
| 312 | HS-20093 | Phase III | 2024-07-04 | SHR-9265 | Camptothecin | CD276; DNA topoisomerase | Shanghai Hansoh Biomedical (China) |
| 313 | HS-20105 | Phase II | 2024-03-01 | SHR-9265 | Camptothecin | Trop-2; TOP1 | Hansoh BioMedical R&D Company |
| 314 | HY-0001-a | Phase II | 2025-07-10 | MMAE | Auristatin | CDCP1 | Sichuan Huiyu Seacross Pharma Technology (China) |
| 315 | IBI-133 | Phase II | 2024-01-16 | Exatecan | Camptothecin | HER3 | Innovent Biologics (China) |
| 316 | IBI-3014 | Phase II | 2025-04-18 | MB3 | Camptothecin | Trop-2; PD-L1 | Innovent Biologics (China) |
| 317 | IBI-343 | Phase III | 2024-06-30 | Exatecan | Camptothecin | Claudin 18.2; TOP1 | Innovent Biologics (China); Takeda Pharmaceuticals |
| 318 | IBI-354 | Phase III | 2025-03-17 | Camptothecin | Camptothecin | HER2; TOP1 | Innovent Biologics (China) |
| 319 | IBI129 | Phase II | 2024-03-12 | Undisclosed | Camptothecin | CD276 | Innovent Biologics (China) |
| 320 | IBI130 | Phase II | 2023-11-14 | Undisclosed | Camptothecin | Trop-2 | Innovent Biologics (China) |
| 321 | Ifinatamab deruxtecan | Phase III | 2024-05-21 | Exatecan | Camptothecin | CD276 | Daiichi Sankyo |
| 322 | ILB-3101 | Phase II | 2024-08-19 | Eribulin | Eribulin | CD276; Tubulin | InnoLake Pharmaceuticals (China) |
| 323 | IRDye800CW-nimotuzumab | Phase II | 2020-09-01 | IRDye800CW | Photosensitizers | Not applicable | University of Saskatchewan |

| | | | | | | | |
|-----|---------------------------|-----------|------------|-------------|--------------|-----------------------------------|---|
| 324 | Izalontamab bregitecan | Phase III | 2023-12-04 | Ed-04 | Camptothecin | EGFR; HER3; TOP1 | Sichuan Baili Pharmaceuticals (China); SystImmune |
| 325 | Izeltabart tapatansine | Phase II | 2020-10-29 | DM21 | Maytansinoid | Tubulin; ADAM9 | Immunogen Inc. |
| 326 | JK-06 | Phase II | 2024-10-23 | MMAE | Auristatin | TPBG; Tubulin | Genekey Biotech |
| 327 | JS-212 | Phase II | 2025-04-11 | Undisclosed | Undisclosed | EGFR; HER3 | Shanghai Junshi Biosciences (China) |
| 328 | JSKN-003 | Phase III | 2023-10-07 | Topo1, Dxd | Camptothecin | HER2; TOP1 | Alphamab Oncology (China) |
| 329 | JSKN-016 | Phase II | 2025-01-17 | Topo1 | Camptothecin | Trop-2; HER3 | Alphamab Oncology (China) |
| 330 | JSKN-033 | Phase II | 2024-01-18 | Topo1 | Camptothecin | HER2; PD-L1; DNA topoisomerase | Alphamab Oncology (China) |
| 331 | KY-0301 | Phase II | 2025-05-01 | MMAE | Auristatin | c-Met; EGFR; Tubulin | Novatim Immune Therapeutics (China) |
| 332 | Ladiratumumab vedotin | Phase II | 2018-02-27 | MMAE | Auristatin | ZIP6; Tubulin | Seagen Inc; MSD |
| 333 | LCB-84 | Phase II | 2023-10-05 | MMAE | Auristatin | Trop-2 | Legochem Biosciences Inc. |
| 334 | LM-305 | Phase II | 2022-12-22 | MMAE | Auristatin | GPRC5D; Tubulin | LaNova Medicines |

| | | | | | | | |
|-----|--------------------------------|-----------|------------|---------------|---------------|----------------|--|
| 335 | LM-350 | Phase II | 2025-09-30 | LDX2 | Camptothecin | CDH17; TOP1 | LaNova Medicines |
| 336 | Lorvotuzumab mertansine | Phase II | 2003-04-01 | DM1 | Maytansinoid | NCAM1; Tubulin | Immunogen Inc. |
| 337 | Lutetium-177 DOTA girentuximab | Phase II | 2005-02-01 | 177 Lu | Radionuclide | CA9 | Wilex AG; Heidelberg Pharma AG; Telix Pharmaceuticals Ltd. |
| 338 | Luveltamab tazevibulin | Phase II | 2023-10-13 | hemiasterlin | Hemiasterlin | FOLR1 | Sutro Biopharma Inc. |
| 339 | LY-4170156 | Phase III | 2025-11-01 | Exatecan | Camptothecin | FOLR1; TOP1 | Lilly; Loxo Oncology Inc. |
| 340 | Maridebart cafraglutide | Phase III | 2025-03-12 | GLP1R agonist | GLP1R agonist | GIPR; GLP1R | Amgen |
| 341 | MBRC-101 | Phase II | 2023-11-07 | MMAE | Auristatin | EPHA5 | MBrace Therapeutics Inc. |
| 342 | MBRC-201 | Phase II | 2025-09-01 | Undisclosed | Undisclosed | Updating | MBrace Therapeutics Inc. |
| 343 | Mecbotamab vedotin | Phase II | 2018-02-15 | MMAE | Auristatin | AXL; Tubulin | Bioatla |
| 344 | MHB-042-C | Phase II | 2025-10-01 | MH30010008 | Camptothecin | c-Met; TOP1 | Minghui Pharmaceutical (China) |
| 345 | MHB-048C | Phase II | 2025-10-01 | MH30010008 | Camptothecin | PSMA | Minghui Pharmaceutical (China) |

| | | | | | | | |
|-----|-----------------------|-----------|------------|------------|--------------|------------------------|--------------------------------------|
| 346 | MHB-088C | Phase III | 2025-06-04 | MH30010008 | Camptothecin | TOP1; CD276 | Minghui Pharmaceutical Pty Ltd |
| 347 | MHB036C | Phase II | 2023-01-23 | MH30010008 | Camptothecin | Trop-2; TOP1 | Minghui Pharmaceutical Pty Ltd |
| 348 | MRG-004A | Phase III | 2025-08-01 | MMAE | Auristatin | TF | Shanghai Miracogen (China) |
| 349 | MRG-006 | Phase II | 2024-07-24 | Topo1 | Camptothecin | GPC3; TOP1 | Shanghai Miracogen (China) |
| 350 | MRG-007 | Phase II | 2025-07-25 | Exatecan | Camptothecin | CDH17; TOP1 | Lepu Biopharma (China) |
| 351 | Naratuximab emtansine | Phase II | 2016-06-05 | DM1 | Maytansinoid | CD37; Tubulin | Immunogen Inc. |
| 352 | OBI-902 | Phase II | 2025-08-04 | Exatecan | Camptothecin | Trop-2 | OBI Pharma |
| 353 | OBI-992 | Phase II | 2024-01-03 | Exatecan | Camptothecin | Trop-2; TOP1 | Biosion |
| 354 | Opelkibart elmanitin | Phase II | 2021-07-21 | Amanitin | Amanitin | RNA polymerase II; KIT | Heidelberg Pharma AG |
| 355 | Ozuriftamab Vedotin | Phase II | 2018-06-27 | MMAE | Auristatin | ROR2; Tubulin | Bioatla |
| 356 | Patritumab Deruxtecan | NDA | 2023-12-22 | Exatecan | Camptothecin | HER3; TOP1 | Daiichi Sankyo; Baxter Oncology GmbH |
| 357 | Pivekimab sunirine | NDA | 2025-09-30 | Sunirine | PBD | IL3RA; DNA | Immunogen Inc; AbbVie |

| | | | | | | | |
|-----|----------------------------|-----------|------------|-------------|--------------|-------------------|---|
| 358 | Praluzatamab ravtansine | Phase II | 2017-06-01 | DM4 | Maytansinoid | CD166 | Immunogen Inc; Cytomx Therapeutics Inc. |
| 359 | Precentabart tocentecan | Phase II | 2025-01-29 | Exatecan | Camptothecin | CEACAM5; TOP1 | Merck |
| 360 | PRO-1160 | Phase II | 2023-03-15 | Exatecan | Camptothecin | CD70 | ProfoundBio |
| 361 | PRO-1286 | Phase II | 2024-11-13 | Exatecan | Camptothecin | EGFR; c-Met; TOP1 | ProfoundBio |
| 362 | Puxitatug Samrotecan | Phase III | 2025-08-01 | AZ14170133 | Camptothecin | VTCN1 | AstraZeneca |
| 363 | PYX-201 | Phase II | 2025-04-15 | PF-06380101 | Auristatin | FN | Pfizer |
| 364 | QLS-5133 | Phase II | 2025-07-01 | QLS6916 | Camptothecin | CDH6; TOP1 | Qilu Pharmaceutical (China) |
| 365 | Raludotatug deruxtecan | Phase III | 2024-02-27 | Exatecan | Camptothecin | TOP1; CDH6 | Daiichi Sankyo |
| 366 | RC-108 | Phase II | 2021-04-08 | MMAE | Auristatin | c-Met; Tubulin | RemeGen (China) |
| 367 | RC-118 | Phase II | 2022-03-03 | MMAE | Auristatin | Claudin 18.2 | RemeGen (China); Biocytogen Pharmaceuticals (Beijing) |
| 368 | RC-278 | Phase II | 2025-08-11 | Undisclosed | Undisclosed | Updating | RemeGen (China) |
| 369 | RC-88 | Phase II | 2020-04-14 | MMAE | Auristatin | MSLN | RemeGen (China) |

| | | | | | | | |
|-----|----------------------|-----------|------------|-------------|--------------|-------------------------|---|
| 370 | Rinatabart Sesutecan | Phase III | 2025-02-07 | Exatecan | Camptothecin | FOLR1; TOP1 | ProfoundBio; Genmab A/S |
| 371 | SGN-PDL1V | Phase III | 2025-09-24 | MMAE | Auristatin | PD-L1; Tubulin | Seagen Inc; Pfizer |
| 372 | SHR-1681 | Phase II | 2025-01-21 | Undisclosed | Undisclosed | Updating | Suzhou Suncadia Biopharmaceuticals |
| 373 | SHR-1826 | Phase II | 2025-02-18 | SHR9265 | Camptothecin | c-Met | Suzhou Suncadia Biopharmaceuticals |
| 374 | SHR-4602 | Phase II | 2024-08-01 | Eribulin | Eribulin | HER2 | Suzhou Suncadia Biopharmaceuticals; 上海盛迪医药有限公司 |
| 375 | SHR-4849 | Phase II | 2025-07-25 | SHR9265 | Camptothecin | DLL3; DNA topoisomerase | Jiangsu Hengrui (China) |
| 376 | SHR-A-1904 | Phase III | 2024-07-16 | SHR9265 | Camptothecin | Claudin 18.2 | Jiangsu Hengrui (China) |
| 377 | SHR-A1912 | Phase III | 2025-04-24 | SHR9265 | Camptothecin | CD79B; TOP1 | Jiangsu Hengrui (China); Suzhou Suncadia Biopharmaceuticals |
| 378 | SHR-A1921 | Phase III | 2024-02-15 | SHR9265 | Camptothecin | Trop-2 | Jiangsu Hengrui (China); Suzhou Suncadia Biopharmaceuticals |
| 379 | SHR-A2009 | Phase III | 2024-11-29 | SHR9265 | Camptothecin | HER3 | Jiangsu Hengrui (China); Suzhou Suncadia Biopharmaceuticals |

| | | | | | | | |
|-----|--------------------|-----------|------------|---------------|--------------|--------------------|---|
| 380 | SHR-A2102 | Phase III | 2025-02-12 | SHR9265 | Camptothecin | NECTIN4; TOP1 | Jiangsu Hengrui (China); Suzhou Suncadia Biopharmaceuticals |
| 381 | Sigvotatug vedotin | Phase III | 2024-02-21 | MMAE | Auristatin | ITGB6; Tubulin | Seagen Inc; Pfizer |
| 382 | SKB-315 | Phase II | 2024-02-28 | KL610023 | Camptothecin | Claudin 18.2; TOP1 | Sichuan Kelun Botai Biomedicine (China) |
| 383 | SKB-410 | Phase II | 2025-03-25 | KL610023 | Camptothecin | NECTIN4 | Sichuan Kelun Botai Biomedicine (China) |
| 384 | SKB-518 | Phase II | 2025-06-05 | Undisclosed | Undisclosed | PTK7 | Sichuan Kelun Botai Biomedicine (China) |
| 385 | SKB-571 | Phase II | 2025-10-20 | DXd | Camptothecin | EGFR; c-Met | Sichuan Kelun Botai Biomedicine (China) |
| 386 | SLC-3010 | Phase II | 2022-12-21 | IL-2 | IL-2R agoist | IL2R | Selexine Inc |
| 387 | SOT-102 | Phase II | 2022-03-31 | PNU-159682 | Doxorubicin | Claudin 18.2 | Sotio Biotech AG |
| 388 | SQ-3370 | Phase II | 2020-08-01 | Doxorubicin | Doxorubicin | DNA; TOP2 | Shasqi Inc. |
| 389 | STI-6129 | Phase II | 2021-04-01 | Duostatin-5.2 | Auristatin | CD38 | Sorrento Therapeutics Inc. |
| 390 | SYS-6002 | Phase II | 2024-04-01 | MMAE | Auristatin | NECTIN4; Tubulin | CSPC Megalith Biopharmaceutial (China); CSPC (China) |

| | | | | | | | |
|-----|--------------------------|-----------|------------|-------------------|--------------|-----------------------|--|
| 391 | SYS-6010 | Phase III | 2024-08-26 | JS-1 | Camptothecin | EGFR | CSPC Megalith Biopharmaceutical (China) |
| 392 | SYS-6043 | Phase II | 2025-10-24 | Top1 i | Camptothecin | CD276 | CSPC Megalith Biopharmaceutical (China) |
| 393 | SYS-6045 | Phase II | 2025-08-01 | tubulin inhibitor | Undisclosed | HER2; Tubulin | CSPC Megalith Biopharmaceutical (China) |
| 394 | SYSA-1801 | Phase III | 2024-12-23 | MMAE | Auristatin | Claudin 18.2; Tubulin | CSPC Megalith Biopharmaceutical (China) |
| 395 | Tabirafusp tedromer | Phase III | 2024-08-23 | Tedromer | Tedromer | IL6; VEGF | Kodiak Sciences Inc. |
| 396 | TAC-001 | Phase II | 2022-06-28 | TLR9 agonist | TLR | TLR9; CD22 | Tallac Therapeutics Inc. |
| 397 | TAK- 188 | Phase II | 2025-09-26 | Undisclosed | Undisclosed | CCR8 | Takeda Pharmaceutical |
| 398 | Tecotabart vedotin | Phase III | 2024-06-24 | MMAE | Auristatin | Claudin 18.2; Tubulin | LaNova Medicines |
| 399 | Telisotuzumab adizutecan | Phase III | 2024-11-08 | A-1743332 | Camptothecin | c-Met; TOP1 | AbbVie |
| 400 | TORL-1-23 | Phase II | 2024-11-20 | MMAE | Auristatin | CLDN6; Tubulin | Torl Biotherapeutics LLC |
| 401 | TQB-2102 | Phase III | 2024-08-01 | DXd | Camptothecin | HER2; TOP1 | Nanjing Chia Tai Tianqing Pharmaceutical (China) |

| | | | | | | | |
|-----|--------------------------|-----------|------------|-----------|--------------|------------------|--|
| 402 | Trastuzumab duocarmazine | NDA | 2022-07-18 | seco-DUBA | Duocarmycin | HER2; DNA | Synthon Bv; Medac Gmbh |
| 403 | Trastuzumab envedotin | Phase III | 2023-07-01 | MMAE | Auristatin | HER2; Tubulin | CSPC Megalith Biopharmaceutical (China) |
| 404 | Trastuzumab pamirtecan | Phase III | 2024-01-18 | P1003 | Camptothecin | HER2;TOP1 | Duality Biologics (China); 3SBio |
| 405 | Trastuzumab vedotin | Phase III | 2021-06-30 | MMAE | Auristatin | HER2; Tubulin | Shanghai Miracogen (China) |
| 406 | Trop2-ADC | Phase II | 2025-03-01 | DXd | Camptothecin | Trop-2 | Sun Yat-Sen Memorial Hospital |
| 407 | TRS-005 | Phase II | 2025-09-01 | MMAE | Auristatin | CD20; Tubulin | Zhejiang Teruisi Pharmaceutical (China) |
| 408 | TUB-030 | Phase II | 2024-12-13 | Exatecan | Camptothecin | TOP1; TPBG | Tubulis GmbH |
| 409 | TUB-040 | Phase II | 2024-06-12 | Exatecan | Camptothecin | NaPi-2b | Tubulis GmbH |
| 410 | Tusamitamab Ravtansine | Phase III | 2020-02-06 | DM4 | Maytansinoid | CEACAM5; Tubulin | Immunogen Inc; Sanofi |
| 411 | Upinitatug rilsodotin | Phase II | 2017-12-12 | AF-HPA | Auristatin | NaPi-2b | Mersana Therapeutics Inc; Adimab LLC. |
| 412 | VBC-101-F11 | Phase II | 2025-09-23 | MMAE | Auristatin | EGFR; c-Met | Velavigo Shanghai Pharmaceutical (China) |
| 413 | VBC-103 | Phase II | 2025-10-01 | TOPOi | Topo | Trop-2; NECTIN4 | VelaVigo Cayman Ltd. |

| | | | | | | | |
|-----|------------------------------|-----------|------------|--------------|--------------|---------------|---|
| 414 | VBP-101 | Phase II | 2024-09-01 | Undisclosed | Undisclosed | CD33 | Vor Biopharma Inc. |
| 415 | Vobramitamab duocarmazine | Phase II | 2023-06-13 | seco-DUBA | Duocarmycin | CD276; DNA | Macrogenics Inc. |
| 416 | WEF-001 | Phase II | 2025-07-28 | MMAE | Auristatin | Updating | Auricula Biosciences Inc. |
| 417 | XNW-27011 | Phase III | 2025-08-12 | Camptothecin | Camptothecin | Claudin 18.2 | Evopoint Biosciences (China); Astellas Pharma |
| 418 | XNW-28012 | Phase III | 2025-07-23 | YL0014 | Camptothecin | TF | Evopoint Biosciences (China) |
| 419 | <u>XYD-9668-198</u> | Phase II | 2023-05-22 | 198 | Camptothecin | Trop-2 | Kunshan Xinyunda Biotechnology (China) |
| 420 | YL-201 | Phase III | 2024-12-17 | YL0010014 | Camptothecin | CD276; TOP1 | Suzhou Medilink Therapeutics (China); Amgen |
| 421 | YL-202 | Phase II | 2023-12-15 | YL0010015 | Camptothecin | HER3; TOP1 | Suzhou Medilink Therapeutics (China) |
| 422 | YL-205 | Phase II | 2024-06-04 | YL0010016 | Camptothecin | TOP1; NaPi-2b | Suzhou Medilink Therapeutics (China) |
| 423 | YL-242 | Phase II | 2025-09-10 | C24 | C24 | VEGF; TOP1 | Suzhou Medilink Therapeutics (China) |
| 424 | YLSH-003 | Phase II | 2025-10-21 | Topo1 | Camptothecin | Updating | Chengdu Easton Biopharmaceuticals (China) |

| | | | | | | | |
|-----|------------------------|------------|------------|------------------|------------------|-------------------|---|
| 425 | Zilovertamab vedotin | Phase III | 2022-01-14 | MMAE | Auristatin | ROR1; Tubulin | Velosbio Inc; Merck Sharp & Dohme LLC |
| 426 | Zocilurtatug pelitecan | Phase III | 2025-10-08 | Camptothecin | Camptothecin | DLL3; TOP1 | Zai Lab (China); Suzhou Medilink Therapeutics (China) |
| 427 | 89Zr-TAK-164 | terminated | 2018-04-23 | DGN549 | PBD | DNA; GUCY2C | Immunogen Inc; Takeda Pharmaceutical |
| 428 | ABBV-787 | terminated | 2023-11-13 | BET degrader | BET degrader | CD33; BET | AbbVie |
| 429 | AbGn-107 | terminated | 2017-04-24 | Auristatin | Auristatin | Not applicable | Altrubio Inc. |
| 430 | AbGn-7 | stalled | 2011-11-01 | Immunomodulators | Immunomodulators | Not applicable | Altrubio Inc. |
| 431 | ADCT-502 | terminated | 2017-05-18 | SG3199 | PBD | HER2; DNA | Cancer Research Technology; Adc Therapeutics Sa |
| 432 | AGS-16C3F | stalled | 2016-05-03 | MMAF | Auristatin | Tubulin; ENPP3 | Agensys Inc. |
| 433 | AGS-5-ME | stalled | 2010-07-01 | MMAE | Auristatin | CTL4; Tubulin | Seagen Inc; Agensys Inc. |
| 434 | AGS-62P1 | terminated | 2016-11-10 | Amberstatin | Auristatin | FLT3 | Ambrx Inc. |
| 435 | AMG-172 | stalled | 2012-01-01 | DM1 | Maytansinoid | CD70; Tubulin | Amgen |
| 436 | AMG-595 | stalled | 2012-02-01 | DM1 | Maytansinoid | EGFRvIII; Tubulin | Amgen |

| | | | | | | | |
|-----|---|------------|------------|--------------|------------------|-----------------|-----------------------------------|
| 437 | Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate | terminated | 2014-12-01 | DM1 | Maytansinoid | KIT; Tubulin | Beijing Novartis Pharma (China) |
| 438 | Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate | terminated | 2019-11-21 | Ricin A | Immunotoxin | CD3; CD7 | Radboud University Medical Center |
| 439 | antibody drug conjugate program 1 for cancer | stalled | 2016-09-24 | Undisclosed | Undisclosed | Updating | AbbVie |
| 440 | Aprutumab ixadotin | terminated | 2015-03-24 | Auristatin | Auristatin | FGFR2; Tubulin | Bayer |
| 441 | AVE-9633 | stalled | 2007-09-01 | DM4 | Maytansinoid | CD33 | Immunogen Inc. |
| 442 | AVID-100 | terminated | 2017-02-01 | DM1 | Maytansinoid | EGFR | Formation Biologics Corp |
| 443 | Azintuxizumab vedotin | terminated | 2015-05-06 | MMAE | Auristatin | SLAMF7; Tubulin | AbbVie |
| 444 | Basiliximab sarotalocan | terminated | 2022-03-24 | IR700 | Photosensitizers | IL2RA | Rakuten Medical Inc. |
| 445 | BAT-8001 | terminated | 2018-07-01 | Maytansinoid | Maytansinoid | Tubulin; HER2 | Bio-Thera Solutions (China) |
| 446 | BAT-8003 | terminated | 2019-03-15 | Batansine | Maytansinoid | Trop-2 | Bio-Thera Solutions (China) |
| 447 | BAY-794620 | terminated | 2009-11-01 | MMAE | Auristatin | CA9 | Bayer |

| | | | | | | | |
|-----|------------------------|------------|------------|------------------|------------------|-------------------|-------------------------------|
| 448 | BIIB-015 | stalled | 2008-06-01 | DM4 | Maytansinoid | Cripto-1; Tubulin | Biogen MA |
| 449 | Bivatuzumab mertansine | terminated | 2002-09-01 | DM1 | Maytansinoid | CD44 | Immunogen Inc. |
| 450 | BMS-986148 | terminated | 2015-06-19 | tubulyisin | Tubulyisin | MSLN | Bristol Myers Squibb |
| 451 | Cantuzumab mertansine | terminated | 2004 | DM1 | Maytansinoid | MUC1 | Immunogen Inc. |
| 452 | Cantuzumab ravtansine | terminated | 2007-05-01 | DM4 | Maytansinoid | CanAg; MUC1 | Immunogen Inc. |
| 453 | CDH17 - IHC Test | stalled | 2024-08-01 | undisclosed | Undisclosed | CDH17 | Arbele Corp |
| 454 | CDX-014 | terminated | 2016-06-01 | MMAE | Auristatin | TIM1; Tubulin | Curagen Corporation; Amgen |
| 455 | CHB 111 | terminated | 2009 | Immunostimulants | Immunostimulants | Not applicable | Virexx Medical Corp |
| 456 | CMB-401 | terminated | 2003 | Calicheamicin | Calicheamicin | MUC1; DNA | Celltech |
| 457 | CMD-193 | terminated | 2004-11-01 | Calicheamicin | Calicheamicin | Lewis-Y antigen | Wyeth Pharmaceuticals Ltd. |
| 458 | Coltuximab ravtansine | terminated | 2011-10-01 | DM4 | Maytansinoid | CD19; Tubulin | Immunogen Inc. |
| 459 | DCLL-9718S | stalled | 2017-11-15 | PBD | PBD | CLEC12A | Roche |
| 460 | Denintuzumab mafodotin | terminated | 2015-10-01 | MMAF | Auristatin | CD19; Tubulin | Seagen Inc. |

| | | | | | | | |
|-----|---------------------------------------|------------|-------------|--------------|------------------|--|---------------------------------|
| 461 | Df-IA2BM-Zr-89 | terminated | 2013-08-01 | 89Zr | Radionuclide | PSMA | Imaginab Inc. |
| 462 | DS-6157 | terminated | 2020-05-08 | Exatecan | Camptothecin | GPR20 | Daiichi Sankyo |
| 463 | EGFRvIII/MMAE antibody drug conjugate | stalled | 2023 | MMAE | Auristatin | Tubulin; EGFRvIII | Abgenix Incorporated |
| 464 | Eramkafusp alfa | terminated | 2016-05-01 | FNAR agonist | FNAR agonist | CD20; IFN- α | Immunogen Inc. |
| 465 | HIV vaccine | stalled | 2010-05-01 | HIV vaccine | Immunostimulants | Not applicable | Celldex Therapeutics |
| 466 | HKT-288 | terminated | 2016-12-01 | DM4 | Maytansinoid | DNA; CDH6 | Beijing Novartis Pharma (China) |
| 467 | HTI-1066 | stalled | 2017-12-31 | SHR152852 | Camptothecin | c-Met | Jiangsu Hengrui (China) |
| 468 | Iladatumab vedotin | stalled | 2015-08-04 | MMAE | Auristatin | Tubulin; CD79B | Roche |
| 469 | IMGN 388 | stalled | 2008-06-01 | DM4 | Maytansinoid | ITGAV&ITGB3; Microtubule-associated proteins | Immunogen Inc; Centocor |
| 470 | IMGN-779 | stalled | 2016-03-01 | DGN462 | PBD | CD33 | Immunogen Inc. |
| 471 | Immunoconjugate | terminated | undisclosed | undisclosed | Undisclosed | Not applicable | Bayer |
| 472 | Indatuximab ravtansine | stalled | 2010-08-01 | DM4 | Maytansinoid | SDC1; Tubulin | Biotest Pharma GmbH |

| | | | | | | | |
|-----|------------------------|------------|------------|--------------|-------------------|------------------|--|
| 473 | Indusatumab vedotin | terminated | 2014-07-02 | MMAE | Auristatin | GUCY2C; Tubulin | Millennium Pharmaceuticals Inc; Seagen Inc. |
| 474 | Ispectamab debotansine | terminated | 2019-08-26 | Maytansinoid | Maytansinoid | BCMA | Celgene |
| 475 | JBH-492 | terminated | 2020-09-07 | DM4 | Maytansinoid | CCR7 | Beijing Novartis Pharma (China) |
| 476 | L-DOS-47 | terminated | 2012-05-01 | Urease | Urease | CEACAM6 | Helix Biopharma |
| 477 | Labetuzumab govitecan | terminated | 2000-02-01 | SN-38 | Camptothecin | CEACAM5; TOP1 | Immunomedics; Ibc Pharmaceuticals Inc. |
| 478 | Laprituximab emtansine | terminated | 2013-10-01 | DM1 | Maytansinoid | EGFR; Tubulin | Immunogen Inc. |
| 479 | Lifastuzumab vedotin | terminated | 2014-02-06 | MMAE | Auristatin | NaPi-2b; Tubulin | Genentech |
| 480 | LM-364 | suspended | 2025-08-01 | Undisclosed | Undisclosed | Updating | LaNova Medicines |
| 481 | lonigutamab ugodotin | terminated | 2017-11-24 | F554443 | IGF1R antagonists | IGF1R | Pierre Fabre Group |
| 482 | LY-256787 | terminated | 1991-05-01 | DAVLB | Auristatin | Tubulin | Lilly |
| 483 | LY-3076226 | stalled | 2015-09-01 | DM4 | Maytansinoid | FGFR3; Tubulin | Lilly |
| 484 | MDX-1203 | stalled | 2009-07-01 | MED-A | Duocarmycin | CD70; DNA | Bristol Myers Squibb |

| | | | | | | | |
|-----|---|------------|------------|------------------------------------|------------------|------------------------|--|
| 485 | MEDI-3726 | stalled | 2017-01-06 | PBD | PBD | DNA | Medimmune; Adc Therapeutics Sa |
| 486 | MEDI-4276 | stalled | 2015-09-23 | AZ13599185 | Auristatin | HER2 | Medimmune Llc. |
| 487 | MEDI-547 | terminated | 2009-08-01 | MMAF | Auristatin | EphA2 | AstraZeneca |
| 488 | Milatumumab doxorubicin | terminated | 2010-07-01 | Doxorubicin | Doxorubicin | TOP2; DNA; HLA-DR | Immunomedics Inc. |
| 489 | Mipasetamab uzoptirine | terminated | 2018-12-21 | SG3199 | PBD | DNA; AXL | Adc Therapeutics Sa |
| 490 | MLN-2704 | terminated | 2003-10-01 | DM1 | Maytansinoid | Tubulin | Immunogen Inc; Millennium Pharmaceuticals Inc. |
| 491 | MM-310 | stalled | 2017-02-22 | Taxol | Taxol | EphA2; Ephrin receptor | Merrimack Pharmaceuticals Inc. |
| 492 | Monoclonal antibody B43 Genistein-conjugate | terminated | 2000-03-01 | RTK inhibitor | RTK i | CD19; RPTKs | University Of Minnesota; Bristol Myers Squibb |
| 493 | MT-6402 | terminated | 2021-05-27 | Cytotoxic T lymphocytes stimulants | Immunostimulants | PD-L1 | Molecular Templates Inc. |
| 494 | NBE-002 | terminated | 2020-06-19 | PNU-159682 | Doxorubicin | ROR1 | Nbe-Therapeutics Ag |

| | | | | | | | |
|-----|---------------------------|------------|------------|---------------|----------------|----------------------------|---------------------------------|
| 495 | NJH-395 | stalled | 2018-12-27 | TLR7 agonist | TLR | HER2; TLR7 | Beijing Novartis Pharma (China) |
| 496 | NNV-019 | suspended | 2019-03-03 | Undisclosed | Undisclosed | CD37 | Nordic Nanovector Asa |
| 497 | OBI-999 | terminated | 2019-11-25 | MMAE | Auristatin | Tubulin; Glycosphingolipid | OBI Pharma |
| 498 | ORM-5029 | terminated | 2022-10-03 | SMol006 | GSPT1 degrader | GSPT1; HER2 | Orum Therapeutics Inc. |
| 499 | PCA-062 | stalled | 2015-04-15 | DM1 | Maytansinoid | CDH3 | Beijing Novartis Pharma (China) |
| 500 | Pertuzumab zuvotolimod | terminated | 2022-02-08 | TLR8 agonist | TLR | TLR8; HER2 | Silverback Therapeutics Inc. |
| 501 | PF-06263507 | terminated | 2013-08-08 | MMAF | Auristatin | TPBG; Tubulin | Oxford Biomedica Plc |
| 502 | PF-06650808 | terminated | 2014-06-01 | Aur0101 | Auristatin | NOTCH3; Tubulin | Pfizer |
| 503 | PF-06664178 | terminated | 2014-08-01 | Aur0101 | Auristatin | Trop-2 | Pfizer |
| 504 | PF-0667263 | terminated | 2014-04-09 | Calicheamicin | Calicheamicin | EFNA4 | Pfizer |
| 505 | PF-06688992 | stalled | 2017-05-16 | Aur0101 | Auristatin | Ganglioside | Pfizer |
| 506 | Pinatuzumab vedotin | stalled | 2012-09-27 | MMAE | Auristatin | Tubulin; CD22 | Genentech |

| | | | | | | | |
|-----|---------------------|------------|------------|-------------|------------------|----------------|--|
| 507 | PRO-1107 | terminated | 2024-01-29 | MMAE | Auristatin | PTK7 | ProfoundBio |
| 508 | PSMA ADC | stalled | 2012-09-01 | MMAE | Auristatin | PSMA; Tubulin | Progenics Pharmaceuticals Inc; Psma Development Company Llc. |
| 509 | REGN-5093-M114 | terminated | 2021-11-09 | M24 | Maytansinoid | c-Met; Tubulin | Regeneron Pharmaceuticals |
| 510 | RFB4-SMPT-dgA | stalled | 1991-07-01 | dgA | Immunotoxin | CD22 | National Cancer Institute; University of Texas Southwestern Medical Center |
| 511 | RG 7598 | stalled | 2011-09-01 | MMAE | Auristatin | Tubulin | Genentech |
| 512 | RG-7600 | stalled | 2011-11-01 | MMAE | Auristatin | MSLN; Tubulin | Genentech |
| 513 | RG-7636 | stalled | 2012-03-01 | MMAE | Auristatin | ETBR; Tubulin | Genentech |
| 514 | RG-7841 | stalled | 2014-04-01 | MMAE | Auristatin | Tubulin; LY6E | Genentech |
| 515 | RG-7861 | stalled | 2015-11-29 | dmDNA31 | Immunostimulants | Not applicable | Genentech |
| 516 | RG-7882 | stalled | 2008-09-01 | MMAE | Auristatin | MUC16 | Genentech |
| 517 | RG-7986 | terminated | 2018 | Undisclosed | Undisclosed | Not applicable | Seagen Inc; Genentech |
| 518 | Rituximab conjugate | stalled | 2013-06-01 | Undisclosed | Undisclosed | CD20 | Biointegrator Llc. |

| | | | | | | | |
|-----|----------------------------|------------|------------|--------------|--------------|-----------------|---|
| 519 | Rolinsatamab talirine | terminated | 2017-07-03 | SGD-1882 | PBD | PRLR; DNA | AbbVie |
| 520 | Rovalpituzumab tesirine | terminated | 2017-02-07 | SCX | PBD | DLL3; DNA | AbbVie; Stemcentrx Inc. |
| 521 | Samrotamab vedotin | stalled | 2015-09-18 | MMAE | Auristatin | LRRC15; Tubulin | AbbVie |
| 522 | SAR-428926 | stalled | 2015-10-05 | DM4 | Maytansinoid | LAMP1; Tubulin | Immunogen Inc; Sanofi |
| 523 | SAR-566658 | terminated | 2017-03-23 | DM4 | Maytansinoid | Tubulin; MUC1 | Immunogen Inc. |
| 524 | SBT-6290 | terminated | 2022-03-01 | TLR8 agonist | TLR | TLR8; NECTIN4 | Silverback Therapeutics Inc. |
| 525 | SC-002 | terminated | 2015-06-01 | PBD | PBD | TAA; | Stemcentrx Inc. |
| 526 | SC-004 | terminated | 2017-06-14 | PBD | PBD | CLDN9; CLDN6; | Taisho Pharmaceutical Holdings Co Ltd. |
| 527 | SC-005 | terminated | 2018-01-04 | Undisclosed | Undisclosed | TAA | AbbVie |
| 528 | SC-006 | terminated | 2017-03-08 | PBD | PBD | DNA | AbbVie |
| 529 | SC-007 | terminated | 2017-09-13 | Undisclosed | Undisclosed | Not applicable | AbbVie; Stemcentrx Inc. |
| 530 | SGN-15 | terminated | 2000-10-01 | Doxorubicin | Doxorubicin | Lewis-Y antigen | Seagen Inc; Bristol Myers Squibb |

| | | | | | | | |
|-----|---------------------|------------|------------|-------------|--------------|------------------|---|
| 531 | SGN-ALPV | terminated | 2022-04-21 | MMAE | Auristatin | ALPP; Tubulin | Seagen Inc. |
| 532 | SGN-CD123A | terminated | 2016-08-01 | PBD | PBD | DNA; IL3RA | Seagen Inc. |
| 533 | SGN-CD19B | terminated | 2016-02-01 | SGD-1882 | PBD | CD19; DNA | Seagen Inc. |
| 534 | SGN-CD228A | terminated | 2019-09-03 | MMAE | Auristatin | MELTF; Tubulin | Seagen Inc. |
| 535 | SGN-CD352A | terminated | 2016-12-01 | PBD | PBD | SLAMF6; DNA | Ligand Pharmaceuticals Inc; Seagen Inc. |
| 536 | SGN-CD47M | terminated | 2019-07-17 | Undisclosed | Undisclosed | CD47 | Seagen Inc. |
| 537 | SGN-CD48A | terminated | 2018-02-20 | MMAE | Auristatin | CD48; Tubulin | Seagen Inc. |
| 538 | SGN-CD70A | stalled | 2014-08-01 | PBD | PBD | CD70; DNA | Seagen Inc. |
| 539 | SHR-A1403 | stalled | 2019-02-13 | SHR152852 | Camptothecin | Tubulin; c-Met | Jiangsu Hengrui (China); |
| 540 | sirtratumab vedotin | stalled | 2013-11-14 | MMAE | Auristatin | SLITRK6; Tubulin | Agensys Inc; Seagen Inc. |
| 541 | Sofituzumab vedotin | stalled | 2011-04-01 | MMAE | Auristatin | MUC16; Tubulin | Genentech |
| 542 | TAA-013 | terminated | 2020-07-22 | DM1 | Maytansinoid | HER2 | Tot Biopharm (China) |
| 543 | TAK-164 | terminated | 2018-04-23 | DGN549 | PBD | DNA; GUCY2C | Immunogen Inc; Takeda Pharmaceutical |

| | | | | | | | |
|-----|---------------------------------------|------------|------------|------------------|------------------|-----------------|--|
| 544 | TAK-500 | terminated | 2022-04-14 | TAK-676 | STING | STING; CCR2 | Takeda Pharmaceutical |
| 545 | Tamrintamab pamoizirine | terminated | 2015-08-01 | SC-DR002 | PBD | DPEP3 | AbbVie; Stemcentrx Inc. |
| 546 | Technetium[99mTc] Monoclonal Antibody | terminated | 1990 | 99mTc | Radionuclide | Not applicable | The Shanghai Cancer Institute |
| 547 | TR1801-ADC | stalled | 2019-08-14 | SG3199 | PBD | c-Met | Tanabe Research Laboratories U.S.A. Inc. |
| 548 | Trastuzumab conjugate | terminated | 2016-09-01 | ADCC | Immunomodulators | HER2 | Biointegrator LLC |
| 549 | Tubutecan antibody drug conjugate | stalled | 2025-05-20 | Exatecan | Camptothecin | TOP1 | Tubulis GmbH |
| 550 | Undisclosed antibody-drug conjugate | stalled | 2016 | Immunomodulators | Immunomodulators | Not applicable | AbbVie; Seagen Inc. |
| 551 | Vadastuximab talirine | terminated | 2016-05-01 | PBD | PBD | CD33; DNA | Seagen Inc. |
| 552 | Vandortuzumab vedotin | stalled | 2011-03-01 | MMAE | Auristatin | Tubulin; STEAP1 | Genentech |
| 553 | Vorsetuzumab mafodotin | terminated | 2009-11-01 | MMAF | Auristatin | Tubulin; CD70 | Seagen Inc. |
| 554 | XMT-1522 | stalled | 2016-11-21 | AF-HPA | Auristatin | HER2 | Mersana Therapeutics Inc; Adimab LLC |
| 555 | XMT-1592 | terminated | 2020-05-11 | MMAF | Auristatin | NaPi-2b | Mersana Therapeutics Inc. |